CCS-RC (Compact Closed System – Rapid Change) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mixing, Granulating, Drying and Coating

DIOSNA presents a compact, closed granulation line in "Rapid Change" design.

It is a complete system for mixing, granulating and drying of pharmaceutical products in the field of R&D and clinical samples.

Interchangeable product containers of different sizes from 10l to 80l are available. The system can be designed for containment applications. All current PAT systems can be integrated. A stainless steel wall in which the HMI is implemented, builds the border to the technical area. This improves the accessibility of technical components for maintenance and reduces cleanroom space.

The exhibit can be seen at the Interpack (Düsseldorf) Hall 3/E01.

Contact: Markus Nowak, Product Manager, Pharma Systems
e-mail markus.nowak@diosna.de
+49 (0)541 33104-814

Diosna Dierks & Söhne GmbH
Am Tie 23
49086 Osnabrűck

www.diosna.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here